Neonatal morbidity and outcome of live born premature babies after attempted illegal abortion with misoprostol.
Misoprostol is a synthetic prostaglandin currently employed to induce labor. Association with illegal abortion has been reported; however, neonatal outcome and morbidity after a failed attempt of abortion has not been described.


OBJECTIVE
To report the association between misoprostol self-medication and preterm labor and to assess perinatal risk factors, morbidity and early outcomes.


METHODS
We conducted a prospective study of all very low birth weight (VLBW) infants delivered in Hospital Fernando Fonseca, during a 5-year period. VLBW infants were assigned to misoprostol group (MG) when preterm delivery was attributed to misoprostol and matched with newborns with similar gestational age, birth- weight, and gender.


RESULTS
During the study period 311 VLBW infants were born. Nineteen belonged to misoprostol group (MG) and 58 were selected for controls. Mothers from MG were significantly younger (21.5 vs 27.5, p = 0.001) and from African origin (74 vs 31%, p = 0.006), had significantly less prenatal care (21 vs 67%, p = 0.000), less antenatal steroids (5 vs 50%, p = 0.001), and were delivered less often by C-section (11 vs 60%, p = 0.000). MG infants had significantly higher rates of patent ductus arteriosus (58 vs 29%, p = 0.031) and chronic lung disease (47 vs 14%, p = 0.026). Mortality rate at 3 months was similar in both groups, but the incidence of abnormal neurodevelopment at 1 year of age was significantly higher in the MG (50 vs 16%, p= 0.02).


CONCLUSIONS
The worse outcome of MG infants seems to be determined by prenatal, natal, and postnatal factors and we believe that misoprostol is probably a significant adjuvant cofactor.
Escumalha
Manuela
M
Department of Paediatrics, Fernando Fonseca Hospital, Lisbon, Portugal.
Gouveia
Catarina
C
Cunha
Manuel
M
Vale
Fernando
F
Machado
Maria-Céu
MC
D000020:Abortifacient Agents, Nonsteroidal; D000024:Abortion, Illegal / Q000009:adverse effects* / Q000706:statistics & numerical data; D000328:Adult; D016022:Case-Control Studies; D002658:Developmental Disabilities / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000453:epidemiology* / Q000209:etiology; D007363:Intensive Care Units, Neonatal; D008297:Male; D008423:Maternal Age; D016595:Misoprostol; D009017:Morbidity; D009035:Mothers / Q000193:education / Q000706:statistics & numerical data; D011174:Portugal / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology*; D011295:Prenatal Care / Q000592:standards; D011446:Prospective Studies; D012111:Residence Characteristics; D012307:Risk Factors; D012651:Self Medication / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol